Raymond James Financial Services Advisors’s Acceleron Pharma XLRN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,550	Closed	-$1.47M	–	3500
2021 Q3	$1.47M	Buy	8,550 +1,876	+28%	+$245K	﹤0.01%	1688
2021 Q2	$838K	Buy	6,674 +1,279	+24%	+$161K	﹤0.01%	2062
2021 Q1	$732K	Buy	+5,395	New	+$697K	﹤0.01%	2058
2019 Q1	–	Sell	-5,111	Closed	-$223K	–	2890
2018 Q4	$223K	Buy	+5,111	New	+$255K	﹤0.01%	2188

Raymond James Financial Services Advisors's XLRN Position: Q4 2021 in Review

Raymond James Financial Services Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 8,550 shares — an estimated $1.47M sold.

Raymond James Financial Services Advisors first reported a position in XLRN in Q4 2018 and held it in 4 quarters. The position peaked at $1.47M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Raymond James Financial Services Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Raymond James Financial Services Advisors sold 8,550 Acceleron Pharma shares in Q4 2021, an estimated $1.47M.
Raymond James Financial Services Advisors first reported a position in Acceleron Pharma in Q4 2018 and held it in 4 quarters.
Raymond James Financial Services Advisors's Acceleron Pharma position peaked at $1.47M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.